Apomorphine
- Generic Name
- Apomorphine
- Brand Names
- Apokyn
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17NO2
- CAS Number
- 58-00-4
- Unique Ingredient Identifier
- N21FAR7B4S
- Background
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
Apomorphine was granted FDA approval on 20 April 2004.
- Indication
Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.
- Associated Conditions
- Mobility decreased
A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2005-09-05
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00145171
Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2005-09-02
- Lead Sponsor
- Mylan Bertek Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT00142545
- Locations
- 🇺🇸
Mylan Pharmaceuticals, Morgantown, West Virginia, United States
JP-1730 to Treat Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2002-06-24
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 30
- Registration Number
- NCT00040209
- Locations
- 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.